德孚在中国

9 7 4 9 1

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

吉非替尼在局部晚期或转移性非小细胞肺癌管理中作用的重要评价

 

Authors Yuan Y, Li XF, Chen JQ, Dong CX, Weng SS, Huang JJ

Published Date May 2014 Volume 2014:7 Pages 841—852

DOI http://dx.doi.org/10.2147/OTT.S34124

Received 24 February 2014, Accepted 6 April 2014, Published 28 May 2014

Abstract: Past studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors can significantly improve clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and sensitive EGFR  gene mutations. Gefitinib (Iressa®), the first oral EGFR tyrosine kinase inhibitor, has been shown to be more effective and better tolerated than chemotherapy either in first-line or second-line treatment for patients with advanced NSCLC harboring sensitive EGFR  mutations. Conversely, among patients with wild-type EGFR, gefitinib is inferior to standard chemotherapy in both the first-line and second-line settings. Further, gefitinib is effective in patients with brain metastases because of its low molecular weight and excellent penetration of the blood–brain barrier. In this review, we summarize the current data from clinical trials with gefitinib and appraise its role in the management of locally advanced or metastatic NSCLC.
Keywords: gefitinib, non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitor


Download Article[PDF]